Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Dexter

Showing results (161-170 of 172) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1994
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancersP J Houghton, P J Cheshire, J C Hallman, et al.
Biochemical Pharmacology|July 15, 1982
Biochemical pharmacology and toxicology of 8-azaadenosine alone and in combination with 2'-deoxycoformycin (pentostatin)E N Spremulli, G W Crabtree, D L Dexter, et al.
Cancer Treatment Reports|March 1, 1983
Biochemical pharmacology and toxicology of formycin alone and in combination with 2'-deoxycoformycin (pentostatin)E N Spremulli, G W Crabtree, D L Dexter, et al.
Investigational New Drugs|August 31, 2002
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642)Desirée Hao, Jinee D Rizzo, Stephanie Stringer, et al.
Cancer Research|November 1, 1985
Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumorsD L Dexter, D P Hesson, R J Ardecky, et al.
Anti-Cancer Drugs|August 1, 1993
XB596, a promising bis-naphthalimide anti-cancer agentS F Chen, D L Behrens, C H Behrens, et al.
Cancer Research|January 1, 1994
Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivityR J McRipley, P E Burns-Horwitz, P M Czerniak, et al.
Leukemia & Lymphoma|May 12, 2023
[<sup>211</sup>At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignanciesGeorge S Laszlo, Brenda M Sandmaier, Allie R Kehret, et al.
International Journal of Oncology|April 11, 2001
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotidesS Agrawal, E R Kandimalla, D Yu, et al.
Leukemia|April 27, 2022
Development of [<sup>211</sup>At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignanciesGeorge S Laszlo, Johnnie J Orozco, Allie R Kehret, et al.
Pageof 18

Showing results (161-170 of 172) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|January 1, 1994
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancersP J Houghton, P J Cheshire, J C Hallman, et al.
Biochemical Pharmacology|July 15, 1982
Biochemical pharmacology and toxicology of 8-azaadenosine alone and in combination with 2'-deoxycoformycin (pentostatin)E N Spremulli, G W Crabtree, D L Dexter, et al.
Cancer Treatment Reports|March 1, 1983
Biochemical pharmacology and toxicology of formycin alone and in combination with 2'-deoxycoformycin (pentostatin)E N Spremulli, G W Crabtree, D L Dexter, et al.
Investigational New Drugs|August 31, 2002
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642)Desirée Hao, Jinee D Rizzo, Stephanie Stringer, et al.
Cancer Research|November 1, 1985
Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumorsD L Dexter, D P Hesson, R J Ardecky, et al.
Anti-Cancer Drugs|August 1, 1993
XB596, a promising bis-naphthalimide anti-cancer agentS F Chen, D L Behrens, C H Behrens, et al.
Cancer Research|January 1, 1994
Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivityR J McRipley, P E Burns-Horwitz, P M Czerniak, et al.
Leukemia & Lymphoma|May 12, 2023
[<sup>211</sup>At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignanciesGeorge S Laszlo, Brenda M Sandmaier, Allie R Kehret, et al.
International Journal of Oncology|April 11, 2001
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotidesS Agrawal, E R Kandimalla, D Yu, et al.
Leukemia|April 27, 2022
Development of [<sup>211</sup>At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignanciesGeorge S Laszlo, Johnnie J Orozco, Allie R Kehret, et al.
Pageof 18